Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence.
about
Sharing Individual Participant Data (IPD) within the Context of the Trial Reporting System (TRS)Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reportsParoxetine-The Antidepressant from Hell? Probably Not, But Caution RequiredThe neuroscience and context of adolescent depressionThe Use of Gene Ontology Term and KEGG Pathway Enrichment for Analysis of Drug Half-LifeReporting of Adverse Events in Published and Unpublished Studies of Health Care Interventions: A Systematic ReviewHow should individual participant data (IPD) from publicly funded clinical trials be shared?Use of Open Access Platforms for Clinical Trial Data.The citalopram CIT-MD-18 pediatric depression trial: Deconstruction of medical ghostwriting, data mischaracterisation and academic malfeasance.Promises and pitfalls of data sharing in qualitative research.Data transparency in clinical trials: Implications of Restoring Study 329.Temporal trends in antidepressant prescribing to children in UK primary care, 2000-2015.Under the Influence: The Interplay among Industry, Publishing, and Drug Regulation.Lessons learned from Restoring Study 329: Transparent reporting, open databases and network meta-analyses as the way forward.Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports.Comparative efficacy of selective serotonin reuptake inhibitors (SSRI) in treating major depressive disorder: a protocol for network meta-analysis of randomised controlled trials.The ICMJE Recommendations and pharmaceutical marketing--strengths, weaknesses and the unsolved problem of attribution in publication ethics.The Role of Psychotropic Medications in the Management of Anorexia Nervosa: Rationale, Evidence and Future ProspectsPublication bias and the canonization of false facts.Spin in RCTs of anxiety medication with a positive primary outcome: a comparison of concerns expressed by the US FDA and in the published literature.What can we learn from publishing endoscopy trial protocols?Efficacy and Safety of Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, and Placebo for Common Psychiatric Disorders Among Children and Adolescents: A Systematic Review and Meta-analysis.Evidence Base Update of Psychosocial Treatments for Child and Adolescent Depression.Reporting of harms outcomes: a comparison of journal publications with unpublished clinical study reports of orlistat trialsThe public debate on psychotropic medication and changes in attitudes 1990-2011.The Mass Production of Redundant, Misleading, and Conflicted Systematic Reviews and Meta-analyses.A systematic review of trial registration and selective outcome reporting in psychotherapy randomized controlled trials.Study 329 continuation phase: Safety and efficacy of paroxetine and imipramine in extended treatment of adolescent major depression.Restoring Study 329: Paroxetine neither effective nor safe for adolescents.Antidepressant use and violent crimes among young people: a longitudinal examination of the Finnish 1987 birth cohort.Marketing trials, marketing tricks - how to spot them and how to stop them.Best practice for analysis of shared clinical trial data.Major depressive disorder and access to health services among people who use illicit drugs in Vancouver, Canada.Academic criteria for appointment, promotion and rewards in medical research: where's the evidence?Conflicts of Interest and the Presence of Methodologists on Guideline Development Panels: A Cross-Sectional Study of Clinical Practice Guidelines for Major Depressive Disorder.Pilot Randomized Controlled Trial of Omega-3 and Individual-Family Psychoeducational Psychotherapy for Children and Adolescents With Depression.Reproducibility of clinical research in critical care: a scoping review.Composition of Canadian Pain Society guideline development group?Benefits, harms and evidence - reflections from UK primary healthcare.Data sharing and reanalysis of randomized controlled trials in leading biomedical journals with a full data sharing policy: survey of studies published in The BMJ and PLOS Medicine.
P2860
Q26771054-77EB430E-28DB-40C4-AA65-0F05D1A65882Q26773320-66A7C813-09B6-4DBD-8ED6-DBFBE08AC25FQ28069392-1634BD90-090A-4326-BEC0-B60E37EF31DCQ28084332-1CEFE596-09B8-4E5B-A25B-EF2B8D30ACB1Q28552953-14E34138-B53E-441B-91A4-7863F96B290DQ28554247-8C8FCFE6-FD22-4E05-9FF2-74DF19F50DACQ28604049-8EBA1D51-C9C5-4953-A106-CC61B8A68616Q30489133-8316982C-9661-4A98-8C85-57114FE5DD38Q31095928-35DF3840-A119-4B5F-BFB4-54F766BC2835Q31122209-6ED347D6-3C9E-4365-B935-8837E4A7183CQ31133233-A1855544-D808-401A-AB31-5E887504A3FCQ33763721-7458B5E9-5A46-4E80-AC0A-62F5B5A37427Q34046215-D642EF32-AA20-4792-A27D-99AB59B2A28DQ34545098-F36D772E-A11E-482B-86FC-F86CCFA2F9FDQ34552333-9BAF3EFD-FF47-4DAE-BF76-CE1E6AAC0519Q36042111-D778282A-9BA2-4786-8EF5-B38C8C2DED48Q36765612-D7F22DED-B266-491A-8D3C-B0B0A053BBCEQ36918091-D27D9EFF-6D44-4A36-847C-B4C3AB3373B8Q37520828-1D6A8DA4-EED8-4A1C-A117-C26B47106B4FQ37728379-18464504-4DCB-41F0-89B3-0A59CD8B352DQ38370911-896DB361-630A-440F-9B19-72C6E0AE6B7DQ38602146-A08AA7DA-CB10-4BE2-B1A4-7850B7AD3294Q38792642-421671BF-B2CB-43D5-8617-5952C5E3DC2BQ38814635-842B34EB-9310-45D5-A975-BC3B5D7461A5Q38937714-A17E241A-8914-4760-8185-8306BE13550BQ38952676-86EC46D8-43E1-4B6D-B5E6-6D227C132EDDQ38968926-F9A7C649-A9F6-40F9-8A03-6368DB80611CQ39192938-C2A2894A-2E8E-40D7-ACC9-CFEC1DB800EEQ39623424-CBE662BE-A595-4B6E-9351-FD217FEC674CQ39646971-BDDA6873-C453-473F-9DAE-4F6C1D879369Q42317700-7E569FD5-35D7-4CEF-8D5F-A22F43E4C5EBQ42423680-94AE16F1-57A8-4164-82FE-5DBAF17AC0EEQ47651528-E08DF90A-41A1-4039-BB1F-05D226F81E9FQ47812171-F3C290AD-33E3-45E1-8172-E028A07E1C8AQ47890905-6E46FEC0-1DEC-4065-BAC0-BCA58E64285BQ48036852-9AE45BC9-32B7-4B67-8E10-712DCF2AB850Q49795224-37EFD5FC-0FD5-4B67-B285-8C7E449548FFQ49875097-D40B05BC-3DA1-47F6-8FBA-A08A13793989Q49956327-CCE111A7-2A09-4907-B7CF-CC8AAD3099A6Q50027688-0ED8C689-671C-4D86-A37B-696121B9C50B
P2860
Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence.
description
2015 nî lūn-bûn
@nan
2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Restoring Study 329: efficacy ...... jor depression in adolescence.
@ast
Restoring Study 329: efficacy ...... jor depression in adolescence.
@en
Restoring Study 329: efficacy ...... jor depression in adolescence.
@nl
type
label
Restoring Study 329: efficacy ...... jor depression in adolescence.
@ast
Restoring Study 329: efficacy ...... jor depression in adolescence.
@en
Restoring Study 329: efficacy ...... jor depression in adolescence.
@nl
prefLabel
Restoring Study 329: efficacy ...... jor depression in adolescence.
@ast
Restoring Study 329: efficacy ...... jor depression in adolescence.
@en
Restoring Study 329: efficacy ...... jor depression in adolescence.
@nl
P2093
P2860
P50
P356
P1433
P1476
Restoring Study 329: efficacy ...... jor depression in adolescence.
@en
P2093
Elia Abi-Jaoude
John M Nardo
Jon Jureidini
P2860
P356
10.1136/BMJ.H4320
P407
P577
2015-09-16T00:00:00Z